Array BioPharma Inc. (Nasdaq: ARRY) entered a collaboration agreement valued at up to $467 million with Novartis to develop the cancer treatments ARRY-162 and ARRY-300. The stock price leaped $1.00 to close at $4.02.
Array BioPharma Enters $467 Million Collaboration Agreement
April 20, 2010 at 16:45 PM EDT
